国际医学(000516) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥845,876,573.04, representing a 13.96% increase year-over-year[3] - The net profit attributable to shareholders was -¥231,362,028.34, a decrease of 2.81% compared to the same period last year[3] - The net profit for Q3 2022 was -845,567,027.07 CNY, compared to -594,151,455.04 CNY in the same period last year, indicating a significant increase in losses[16] - Operating profit for Q3 2022 was -844,797,210.13 CNY, worsening from -573,099,834.99 CNY year-over-year[16] - The company reported a total comprehensive loss of -845,567,027.07 CNY for the period, compared to -594,151,455.04 CNY last year[17] - Basic and diluted earnings per share were both -0.3634 CNY, worsening from -0.2641 CNY in the previous year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥2,803,634.80, reflecting a significant decrease of 101.76% year-over-year[3] - Net cash flow from operating activities was -2,803,634.80, a significant decrease from 159,391,376.23 in the previous period[19] - Total cash inflow from investment activities was 1,049,534,736.13, down from 2,641,357,872.76 in the prior period[19] - Cash outflow from investment activities totaled 1,618,157,380.48, compared to 4,414,384,950.21 previously, resulting in a net cash flow of -568,622,644.35[19] - Cash inflow from financing activities was 777,619,600.00, a decrease from 2,120,819,899.01 in the last period[19] - Net cash flow from financing activities was 46,620,668.65, down from 1,389,095,808.94 in the previous period[19] - The ending cash and cash equivalents balance was 994,285,889.98, compared to 734,933,499.02 at the end of the previous period[19] - Cash outflow for employee payments increased to 979,061,713.60 from 848,032,985.04[19] - Total cash outflow from operating activities was 2,115,497,127.13, compared to 1,860,771,343.41 previously[19] - Cash inflow from recovering investments was 944,973,491.64, down from 2,500,370,058.84 in the prior period[19] - The company received tax refunds totaling 203,665,328.19 during the reporting period[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥12,661,602,703.85, down 4.94% from the end of the previous year[3] - The equity attributable to shareholders decreased by 12.37% to ¥4,666,779,589.77 compared to the end of the previous year[3] - Total liabilities amounted to CNY 7,999,659,442.52, slightly up from CNY 7,988,793,342.79 in the previous year[15] - The company's total assets decreased to CNY 12,661,602,703.85 from CNY 13,320,275,545.11 year-over-year[15] - Short-term borrowings increased significantly to CNY 614,643,609.69 from CNY 225,840,472.52, marking a 172.00% rise[15] - Non-current liabilities totaled CNY 4,370,349,428.12, down from CNY 4,493,206,560.09 in the previous year[15] - The company's equity attributable to shareholders decreased to CNY 4,666,779,589.77 from CNY 5,325,517,348.40 year-over-year[15] - Current assets totaled CNY 1,738,524,326.06, down 25.41% from CNY 2,331,003,303.45 year-over-year[14] - Accounts receivable rose to CNY 460,919,638.02, an increase of 26.00% compared to CNY 365,883,073.06 in the previous year[14] - Inventory decreased slightly to CNY 81,313,262.03 from CNY 84,077,981.90, a decline of 3.25%[14] Strategic Initiatives - The company signed a strategic cooperation agreement with Wenzhou Medical University on August 12, 2022, to enhance clinical teaching and medical talent training[10] - The company aims to establish a high-level talent training base and a high-quality medical service demonstration base through its collaboration with Wenzhou Medical University[10] - The strategic partnership with Wenzhou Medical University is expected to foster academic exchanges and resource sharing in medical research and public health[10] - The company approved a restricted stock incentive plan for 138 core technical and management personnel, granting up to 7,662,313 shares, with performance targets set for revenue growth rates of 80%, 85%, and 165% for the years 2021, 2022, and 2023 respectively[11] - The company’s performance assessment indicators for the incentive plan were adjusted due to the impact of COVID-19 on its medical services[11] - The company is focused on optimizing its business structure and enhancing its comprehensive strength through new specialized services[12] Expenses - Total operating costs increased to CNY 2,713,905,628.44, up 6.29% from CNY 2,553,360,139.15 in Q3 2021[15] - Research and development expenses increased to 9,456,290.06 CNY from 7,511,041.98 CNY, reflecting a 26% rise[16] - Financial expenses rose to 138,903,846.53 CNY, up from 119,817,441.59 CNY, marking a 16% increase[16] - The tax expenses for the quarter were 370,551.10 CNY, significantly lower than 11,264,337.76 CNY in the same quarter last year[16] - The company experienced a foreign exchange loss of -62,560,971.84 CNY, an improvement from -91,060,283.16 CNY in the previous year[16] - Non-recurring losses totaled -¥22,524,596.85 for the current period, with significant impacts from fair value changes of financial assets[4] - The company recorded a net investment loss of 11,533,305.25 CNY, down from 18,606,940.38 CNY year-over-year[16]